TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Frequently asked questions
What sector does TransMedics Group, Inc (TMDX) operate in?
TransMedics Group, Inc belongs to the Healthcare sector and operates in the Medical Devices industry.
What is TransMedics Group, Inc (TMDX) current stock price?
As of the latest data, TransMedics Group, Inc stock price is $90.79, with a previous close of $93.60. TransMedics Group, Inc lost -$2.81 in the last trading session, representing a -3% loss.
What is TransMedics Group, Inc (TMDX) current market capitalization?
TransMedics Group, Inc market cap is approximately 3.14 billion.
What is TransMedics Group, Inc (TMDX) Earnings Per Share (EPS)?
The trailing EPS is $3.86, and the forward EPS is $2.31.
What is TransMedics Group, Inc (TMDX) Price-to-Earnings (P/E) ratio?
TransMedics Group, Inc current P/E ratio is 23.52, with a forward P/E of 39.38.
What is TransMedics Group, Inc (TMDX) EBITDA?
TransMedics Group, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 26.63 million.
Does TransMedics Group, Inc (TMDX) pay dividends?
No. TransMedics Group, Inc does not pay a dividend.
How did TransMedics Group, Inc (TMDX) perform in its most recent earnings report?
In the last report (June 30, 2026), TransMedics Group, Inc posted an EPS surprise of -12% and a revenue surprise of 3.24%.
What is TransMedics Group, Inc (TMDX) beta (volatility) score?
TransMedics Group, Inc has a beta of 1.880, suggesting it is more volatile than the market.